DS 7250
Alternative Names: DS-7250Latest Information Update: 07 Aug 2013
At a glance
- Originator Daiichi Sankyo Company
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Diacylglycerol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 31 Jul 2013 Discontinued - Phase-I for Diabetes mellitus in European Union (PO)
- 31 Jul 2013 Discontinued - Phase-I for Diabetes mellitus in USA (PO)
- 31 Jul 2013 Discontinued - Phase-I for Obesity in European Union (PO)